Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 88 | 0.82 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 13061
Sealed predictions
- MGRN1 in dopamine neurons, braak-0.26 (p 0.493) → -0.37 (p 0.329)receipt 13068
Swarm cases
receipt 13068: MGRN1 in dopamine neurons, braak
- power
- full sample -0.38 (p 0.120, n 18), 95% CI -0.72 to +0.11. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.41 (p 0.091, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.42 (p 0.080, n 18). could be the mix.
- skeptic
- leave-one-out range -0.50 to -0.30, sign flips 0; without severely affected donors -0.38 (p 0.120, n 18). fragile.
- cell type
- strongest in OPCs: -0.61 (p 0.0075, n 18) vs -0.38 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MGRN1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MGRN1 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.57 p 0.041 (needs p < 1.7e-4)
Receipts
loading the receipts